Galena Biopharma Inc (GALE): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Galena Biopharma ( GALE) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 2.6%. By the end of trading, Galena Biopharma rose $0.10 (2.6%) to $3.95 on average volume. Throughout the day, 7,393,563 shares of Galena Biopharma exchanged hands as compared to its average daily volume of 9,390,000 shares. The stock ranged in a price between $3.86-$4.24 after having opened the day at $4.22 as compared to the previous trading day's close of $3.85. Other companies within the Drugs industry that increased today were: Flexion Therapeutics ( FLXN), up 11.8%, Cormedix ( CRMD), up 10.7%, Cara Therapeutics ( CARA), up 8.8% and Imprimis Pharmaceuticals ( IMMY), up 8.1%.

Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing oncology treatments to address major unmet medical needs to advance cancer care. It is developing a pipeline of immunotherapy product candidates for the treatment of various cancers based on the E75 peptide. Galena Biopharma has a market cap of $420.9 million and is part of the health care sector. Shares are down 22.4% year to date as of the close of trading on Thursday. Currently there are 8 analysts that rate Galena Biopharma a buy, 1 analyst rates it a sell, and none rate it a hold.

TheStreet Ratings rates Galena Biopharma as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and feeble growth in its earnings per share.

On the negative front, Compugen ( CGEN), down 20.1%, Medivation ( MDVN), down 14.9%, Kindred Biosciences ( KIN), down 14.6% and Auspex Pharmaceuticals ( ASPX), down 14.4% , were all laggards within the drugs industry with Gilead ( GILD) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Dow Falls, S&P 500 Trades Lower as P&G and Apple Slump

Dow Falls, S&P 500 Trades Lower as P&G and Apple Slump

Video: Jim Cramer on Apple, Procter & Gamble, Nucor and Acacia Communications

Video: Jim Cramer on Apple, Procter & Gamble, Nucor and Acacia Communications

Video: Jim Cramer Reveals Why Stocks Are Moving Lower Thursday

Video: Jim Cramer Reveals Why Stocks Are Moving Lower Thursday

Soaring Nickel Prices Could Be Bad News for Electric Carmakers Like Tesla

Soaring Nickel Prices Could Be Bad News for Electric Carmakers Like Tesla

Video: The Road to S&P 500 2,800 Is 'Slow and Choppy'

Video: The Road to S&P 500 2,800 Is 'Slow and Choppy'